FDA approved an expanded indication for ENBREL (etanercept) to inhibit progression of structural damage of active arthritis
On Aug. 25, 2003, the FDA approved an expanded indication for ENBREL (etanercept) to inhibit the progression of…
On Aug. 25, 2003, the FDA approved an expanded indication for ENBREL (etanercept) to inhibit the progression of…
On Jun. 20, 2003, Genentech drug Xolair (omalizumab) was approved by the U. S. Food and Drug Administration…
On Jun. 16, 2003, researchers at Stanford University Medical Center announced they found that a drug commonly prescribed…
On May 30, 2003, the Attorney General of California consented to the sale of the assets of the…
On May 22, 2003, Amgen announced it was relocating its cancer research division to Seattle following its acquisition…
On Apr. 27, 2003, Stanford researchers found that Wnt genes, first discovered as critical genes in cancer, are…
On Jan. 10, 2003, long-term efficacy and safety of etanercept (Enbrel) was found in children with polyarticular-course juvenile…
On Dec. 3, 2002, Genentech drug Pegasys (peginterferon alfa-2a) was approved by the Food and Drug Administration (FDA)…
On Aug. 5, 2002, President George W. Bush appointed Richard H. Carmona as U.S. Surgeon General, one of…
On Jul. 22, 2002, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved Aranesp (darbepoetin…
On Jul. 16, 2002, Amgen completed it’s acquisition of Immunex Corporation for $16 billion in stock and net…
On Jul. 2, 2002, the University of California, Davis Comprehensive Cancer Center announced it had received National Cancer…
On Apr. 15, 2002, BOTOX(R) cosmetic (onabotulinumtoxinA), manufactured by Allergan, was approved by the Food and Drug Administration…
On Mar. 26, 2005, The University of Southern California/Norris Comprehensive Cancer Center in Los Angeles announced a $15…
In 2002, Stanford researchers became the first to use RNAi to switch off genes in mice.
In 2002, Stanford researchers became the first to use gene expression profiling to predict cancer outcomes. The research…
On Dec. 17, 2001, the acquisition of Immunex by Amgen was announced for $16 billion in stock and…
On Nov. 19, 2001, researchers at Lucile Packard Children’s Hospital at Stanford announced they had identified a novel…
On Sept. 13, 2001, the Food and Drug Administration (FDA) announced it had approved Genentech’s request for it’s…
On Mar. 29, 2001, the Food and Drug Administration (FDA) announced it had approved Genentech’s drug Valcyte (valganciclovir…
On Jan. 10, 2001, Livermore National Laboratory announced a partnership with BioLuminate to develop ‘Smart Probe’ tool for…
In 1978, Moores Cancer Center (MCC) at UC San Diego achieved National Cancer Institute (NCI) designated comprehensive cancer…
On Dec. 16, 2002, researchers at Stanford University Medical Center announced they were continuing a multi-year clinical trial…
On Sept. 22, 2000, Pathogenesis was acquired by Emeryville, California-based Chiron for $660 million or $38.50 per share….
On Jul. 11, 2000, Stanford researchers announced they had identified a substance commonly added to toothpaste to prevent…
On June 2, 2000, the U.S. Food and Drug Administration announced it had approved Genentech’s drug TNKaseᆴ (tenecteplase)….
On Apr. 24, 2000, Stanford researchers announced they have solved the structure of the RNA polymerase protein, one…
On Jan. 10, 2012, the Norris Foundation made a $15 million commitment toward construction of the Harlyne J….
In 2000, the Center for Clinical Sciences Research building opened, and is an example of a fully integrated…
In 2000, QB3 founded as the University of California’s hub for innovation and entrepreneurship in life science, with…